Hauser, Robert A.
Promising medical therapies for Parkinson's disease [electronic resource] / Robert A. Hauser. - London : Henry Stewart Talks, 2014. - 1 online resource (1 streaming video file (41 min.) : color, sound). - Parkinson's disease, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Parkinson's disease. .
Animated audio-visual presentation with synchronized narration. Title from title frames.
Contents: Selected Future Therapies for Motor Fluctuations and Dyskinesias -- Ankiparkinsonian agents -- A2a antagonists -- Levodopa preparations -- VR040 (inhaled apomorphine) -- Safinamide (mixed MOA : MAO-B and glu inhibition) -- Anti-dyskinetics -- AFQ056 : mGluR5 antagonist -- ADX48621 (dipraglurant) : mGluR5 negative allosteric modulator -- Fipamezole :a2 adrengergic receptor antagonist -- ADS-5102 : sustained release amantadine.
Access restricted to subscribers.
Mode of access: World Wide Web.
3754 Henry Stewart Talks
Antiparkinsonian agents--Side effects.
Antiparkinsonian agents.
Dopa--Physiological effect.
Parkinson's disease--Chemotherapy.
Parkinson's disease--Treatment.
Adenosine A2 Receptor Antagonists.
Antiparkinson Agents--adverse effects.
Antiparkinson Agents--therapeutic use.
Apomorphine--pharmacokinetics.
Benzylamines--pharmacokinetics.
Dopamine Agonists.
Dyskinesia, Drug-Induced--prevention & control.
Levodopa--therapeutic use.
Parkinson Disease--drug therapy.
Parkinson Disease--therapy.
Receptor, Metabotropic Glutamate 5--antagonists & inhibitors.
Promising medical therapies for Parkinson's disease [electronic resource] / Robert A. Hauser. - London : Henry Stewart Talks, 2014. - 1 online resource (1 streaming video file (41 min.) : color, sound). - Parkinson's disease, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Parkinson's disease. .
Animated audio-visual presentation with synchronized narration. Title from title frames.
Contents: Selected Future Therapies for Motor Fluctuations and Dyskinesias -- Ankiparkinsonian agents -- A2a antagonists -- Levodopa preparations -- VR040 (inhaled apomorphine) -- Safinamide (mixed MOA : MAO-B and glu inhibition) -- Anti-dyskinetics -- AFQ056 : mGluR5 antagonist -- ADX48621 (dipraglurant) : mGluR5 negative allosteric modulator -- Fipamezole :a2 adrengergic receptor antagonist -- ADS-5102 : sustained release amantadine.
Access restricted to subscribers.
Mode of access: World Wide Web.
3754 Henry Stewart Talks
Antiparkinsonian agents--Side effects.
Antiparkinsonian agents.
Dopa--Physiological effect.
Parkinson's disease--Chemotherapy.
Parkinson's disease--Treatment.
Adenosine A2 Receptor Antagonists.
Antiparkinson Agents--adverse effects.
Antiparkinson Agents--therapeutic use.
Apomorphine--pharmacokinetics.
Benzylamines--pharmacokinetics.
Dopamine Agonists.
Dyskinesia, Drug-Induced--prevention & control.
Levodopa--therapeutic use.
Parkinson Disease--drug therapy.
Parkinson Disease--therapy.
Receptor, Metabotropic Glutamate 5--antagonists & inhibitors.